![](https://wp-static.smartkarma.com/../assets/uploaded/2023/03/DailyBriefChinaJDHealthFirstPacificCoInnerMongoliaYiliIndustrialGroupAandmore.jpg)
In today’s briefing:
- JD Health: Lower Margin Direct Sales Biz Weighs Down Profitability
- Weekly Wrap – 24 Mar 2023
- Weekly Wrap – 24 Mar 2023
- Yilli: Aggressions Backfired
JD Health: Lower Margin Direct Sales Biz Weighs Down Profitability
- JD Health reported 2H2022 results. 2H revenue increased 55.5% YoY to RMB26.5bn (RMB24.2bn) while fall in GPM and an increase in fulfilment costs led to operating losses during the period.
- Product revenues (JD Pharmacy) continues to account for a majority of JD Health’s revenues that generate lower GPM compared to Marketplace and other revenues.
- JD Health’s share price has moved up over the last few months but further decline in GPM could pull the share price down suggesting it could be a Good Short.
Weekly Wrap – 24 Mar 2023
Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.
In this Insight:
and more…
Weekly Wrap – 24 Mar 2023
Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.
In this Insight:
and more…
Yilli: Aggressions Backfired
- Yilli’s aggressive marketing in 2Q raised market concerns over intensifying competition
- An outright price war is unlikely as its closest competitor, Mengniu, is not willing to follow suit
- Margin remains under pressure on rising input cost
- Trimmed fair value to CNY22.5 (from CNY26.1)
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars